CLBS 03

Drug Profile

CLBS 03

Alternative Names: CD4+CD127lo/-CD25+ polyclonal Treg adoptive immunotherapy; CD4+CD127lo/-CD25+ polyclonal Tregs; CLBS03; Ex vivo expanded human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells; NBS 03; NBS03A; NBS03D; NSB-03; NSB-03A; NSB-03D; Regulatory T cell therapy - Athelos Corporation/Becton, Dickinson and Company; Regulatory T lymphocyte cell therapy - Athelos; T cell replacement therapy - Athelos Corporation/Becton, Dickinson and Company; Treg cells - Caladrius Biosciences

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Becton, Dickinson and Company
  • Developer Athelos Corporation; Becton, Dickinson and Company; Caladrius Biosciences; Sanford Health; University of California at San Francisco
  • Class Antiasthmatics; Antihyperglycaemics; Regulatory T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Preclinical Asthma
  • Research Transplant rejection
  • No development reported Graft-versus-host disease; Multiple sclerosis; Systemic lupus erythematosus

Most Recent Events

  • 08 Mar 2018 Interim adverse events data from a phase II trial in Type-1 diabetes mellitus released by Caladrius Biosciences
  • 18 Jan 2018 Caladrius Biosciences completes enrolment in the phase II T-Rex trial for Type-1 diabetes mellitus (In adolescents) in USA (NCT02691247)
  • 06 Sep 2016 Caladrius Biosciences completes enrolment in the first patient cohort in the T-Rex phase II trial for Type-1 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top